Guggenheim analyst Vamil Divan lowered the firm’s price target on AbbVie (ABBV) to $212 from $221 and keeps a Buy rating on the shares. The ...

559-9005 Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116 AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with AbbVie Inc. (NYSE ...

There are several Canadian companies that offer funds that invest in U.S. stocks with a covered call strategy. One is ...

Monday was a grim day for a great many stocks, but luckily for its investors, AbbVie (NYSE: ABBV) wasn't one of them. The ...

AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit margin of ...

We recently published a list of the 12 Best Stocks to Buy in 2025 for Beginners. In this article, we are going to take a look ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $212.73, a high ...

Investors who were hoping for huge dividend increases may want to adjust their expectations. Today, AbbVie's dividend payout ratio is 61% of 2024 earnings. That leaves plenty of room for future ...

AbbVie Inc (Symbol: ABBV ... and others, which make up an investor community featuring stock message boards, ratings, research, and strategies. BNK Invest caters to investing firms and individual ...